Physicians' Academy for Cardiovascular Education

Covid-19, ACE2, RAASi

COVID-19, ACE2 and RAAS inhibition

EBAC-accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

The aim of this course is to provide cardiovascular physicians with current insights in ACE2 and the use of RAASi in the management of patients with COVID-19. Member registration (free) is needed to enroll in this course.

COVID-19, ACE2 and RAAS inhibition

Lecture - Apr. 29, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein
Watch a webinar on COVID-19, ACE2 and RAAS inhibition, including presentations on a scientific perspective and a clinical perspective, and in the end a discussion by 3 experts.

Watch a webinar on COVID-19, ACE2 and RAAS inhibition, including presentations on a scientific perspective and a clinical perspective, and in the end a discussion by 3 experts.

COVID-19, ACE2 and RAASi - a scientific perspective

10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on the scientific data that is available on the ACE2 receptor and RAAS inhibitors.

This presentation is part of a webinar on COVID-19, ACE2 and RAAS inhibition and focusses on scientific data that is available on the ACE2 receptor and RAAS inhibitors.

A clinical perspective on COVID-19, ACE2 and RAAS inhibition

10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents what the clinical implications are of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

As part of a webinar on COVID-19, ACE2 and RAASi, prof. Epstein presents clinical implications of discontinuation of RAASi in COVID-19 patients and strongly recommends to continue use of these medications.

COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?

10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein
As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

As many questions arise on COVID-19, ACE2 and RAAS inhibition, 3 experts discuss some of the issues on this topic as part of a webinar.

No evidence that RAS blockers facilitate SARS-CoV-2 entry into cells

Literature - Apr. 14, 2020 - Danser AHJ et al., - Hypertension 2020

This commentary article describes the function of ACE2, the receptor responsible for SARS-CoV-2 entry, and describes why continued use of RAS blockers during the COVID-19 pandemic is recommended.